Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and ...
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SIM0505 for the treatment of women with platinum resistant ovarian cancer (PROC) Phase 1 data for SIM0505 to be ...
Technion researchers part of international study that validates fast, accessible alternative to genomic tests using routine ...
Fast Track status enables closer FDA engagement to potentially accelerate development of a CDH6-directed ADC in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results